Key points

• The vaccines currently used in France are approximately 50% effective against symptomatic SARS-CoV-2 infection after a single dose

• 92.3% efficacy against Alpha, 84.5% against Delta, and 68.6% against Omicron, eight to thirty days after the initial vaccination series

• 63.8% and 74.1% efficacy against Delta three to four months after completion of the primary vaccination series with the Cominarty® (Pfizer-BioNTech) and Spikevax® (Moderna) vaccines

• Only 19.8% and 27.4% efficacy against Omicron three to four months after completion of the primary vaccination series with the Cominarty® (Pfizer-BioNTech) and Spikevax® (Moderna) vaccines

• Over 90% efficacy against Delta but approximately 50% against Omicron, two to four months after the mRNA vaccine booster

• Spikevax® vaccine efficacy is higher than that of the Cominarty® vaccine, particularly in people aged 50 and older